The FDA has given Teva tentative approval to begin selling a generic version in 2012.  Teva states the patent for 2019 is invalid and a generic product will not infringe.  This goes back to 2004 when Teva notified Pfizer of their intention.  Pfizer on the other hand didn’t have such good luck in the US Trademark Office and denied the copyright saying it resembled the active ingredient in “Horny Goat Weed”.  The link below contains so other interesting alternatives to treat ED as well including a device that supposedly “cures” in a short amount of time too.  

Viagra Patent Rejected By US Trademark Office – Not Much Different Than Horny Goat Weed

As you can see there are some lab studies going on with the weed too.  Teva is very busy in court these days challenging patents to bring more generics to market.  There’s a few more under the related links below to read about. 

"Horny Goat Weed" Shows Promise In Lab Studies as alternative for Viagra

If you are curious as to how much the drug costs, the link below will give you an idea, and it’s not cheap.  Viva Teva!  BD 

What Does Viagra Cost?

Pfizer Inc. has sued generic maker Teva Pharmaceuticals Industries Ltd. in federal court to block a copycat version of its Viagra erectile-dysfunction drug from being sold in the U.S. until 2019.

Israel-based Teva has tentative approval from the U.S. Food and Drug Administration to sell a generic of the drug upon the March 2012 expiration of its primary patent, covering its composition, according to the suit. Viagra, which brought $1.9 billion in world-wide sales for Pfizer in 2009, is also covered by patent expiring in October 2019 that covers its use in erectile dysfunction.

Method-of-use patents allow companies to patent a new use for an already covered compound, but they often aren't considered as strong as an original composition-of-matter patent

Pfizer Sues Teva Over Generic Viagra - WSJ.com

Related Reading:

FDA To Review Teva Biosimilar of Amgen's Neupogen – Authority to Approve? Only Our Congress Knows

Teva Pays Off Novartis – One Legal Battle Over A Patent Comes to an End With Generic Famvir

Drug Deals – Nexium and Teva Purple Pill Agreement, And What Is This Costing Us?

Generic Prevacid SoluTab Is Here – Teva Wins Court Battle on Patent Challenge For Heartburn Drug

Teva Wins Again – Merck’s Patent on Temodar Chemotherapy Drug Not Enforceable

Teva Suing Amgen Over Intellectual Property Infringement – Sensipar for Kidney Disease

Merck and Singulair – More Legal Battles Besides Teva With Patent Challenges

1 comments :

  1. I think that its only the FDA who know the real truth. Hope that the decision comes out for good.

    ReplyDelete

 
Top
Google Analytics Alternative